ScreenerHero

CUVL Clinuvel Pharmaceuticals Limited

NAS · US · Healthcare · Biotechnology · clinuvel.com
5.800USD+2.29%Mkt Cap: 292.83M $P/E: 12.89

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap292.83M USD
Enterprise Value35.81M USD
Revenue (TTM)94.02M USD
Gross Profit78.21M USD
Net Income (TTM)33.92M USD
Revenue/Share1.88 USD
Last Price5.800 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.89
P/E (Forward)—
PEG—
EV/EBITDA0.87
EV/Revenue0.38
P/S3.04
P/B1.50
EPS (TTM)0.46
EPS (Forward)—
52W Range
5.6006% of range8.920
52W High8.920 USD
52W Low5.600 USD
Profitability
Gross Margin83.18%
Oper. Margin47.32%
EBITDA Margin43.72%
Profit Margin36.07%
ROE12.43%
ROA11.49%
Growth
Revenue Growth-3.80%
Earnings Growth5.30%
Cash Flow & Leverage
Operating CF36.91M USD
CapEx (TTM)1.60M USD
FCF Margin27.00%
FCF Yield8.67%
Net Debt-250.12M USD
Net Debt/EBITDA-6.08
Balance Sheet
Debt/Equity0.01
Current Ratio14.81
Quick Ratio14.34
Book Value/Sh3.77 USD
Cash/Share5.00 USD
Dividends
Fwd Div Rate0.04 USD
Trail. Div Rate0.05 USD
Div. Yield0.63%
5Y Avg Yield0.24%
Payout Ratio7.67%
Ex-Div DateSep 8, 2026
Pay DateSep 28, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.50.43M
Float44.03M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio1.0d
Short % Out.0.05%
Shares Short26.44K
Short (prev mo.)1.16K
Technical
SMA 506.417 (-9.6%)
SMA 2007.072 (-18.0%)
Beta0.58
S&P 52W Chg16.45%
Avg Vol (30d)18.68K
Avg Vol (10d)7.25K
Technical Indicators
RSI (14)44.1
MACD-0.2029
MACD Signal-0.2353
MACD Hist.+0.0324
BB Upper6.063 USD
BB Middle5.836 USD
BB Lower5.609 USD
BB Width7.77%
ATR (14)0.2508 USD
Vol Ratio (20d)0.12x